SillaJen Inc (215600) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SillaJen Inc (215600) has a cash flow conversion efficiency ratio of -0.040x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.74 Billion ≈ $-3.21 Million USD) by net assets (₩117.80 Billion ≈ $79.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SillaJen Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how SillaJen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 215600 liabilities breakdown for a breakdown of total debt and financial obligations.
SillaJen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SillaJen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CapMan Oyj B
HE:CAPMAN
|
0.000x |
|
Cabaletta Bio Inc
NASDAQ:CABA
|
-0.315x |
|
Guangzhou Jet Bio-Filtration Co Ltd
SHG:688026
|
0.037x |
|
Vivien Corp
KO:002070
|
-0.043x |
|
Summit Midstream Corporation
NYSE:SMC
|
0.024x |
|
Haverty Furniture Companies Inc
NYSE:HVT
|
0.104x |
|
Beijing New Universal Science and Technology Co Ltd
SHE:300472
|
0.155x |
|
Eimskipafélag Íslands hf
IC:EIM
|
0.020x |
Annual Cash Flow Conversion Efficiency for SillaJen Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of SillaJen Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see SillaJen Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩131.82 Billion ≈ $89.33 Million |
₩-17.83 Billion ≈ $-12.08 Million |
-0.135x | +54.44% |
| 2023-12-31 | ₩57.31 Billion ≈ $38.84 Million |
₩-17.02 Billion ≈ $-11.53 Million |
-0.297x | -5.86% |
| 2022-12-31 | ₩78.94 Billion ≈ $53.50 Million |
₩-22.14 Billion ≈ $-15.00 Million |
-0.280x | +50.07% |
| 2021-12-31 | ₩108.05 Billion ≈ $73.22 Million |
₩-60.69 Billion ≈ $-41.13 Million |
-0.562x | +43.98% |
| 2020-12-31 | ₩22.88 Billion ≈ $15.51 Million |
₩-22.94 Billion ≈ $-15.55 Million |
-1.003x | -241.83% |
| 2018-12-31 | ₩165.09 Billion ≈ $111.88 Million |
₩-48.43 Billion ≈ $-32.82 Million |
-0.293x | -275.11% |
| 2017-12-31 | ₩201.95 Billion ≈ $136.86 Million |
₩33.83 Billion ≈ $22.93 Million |
0.168x | +117.60% |
| 2016-12-31 | ₩207.97 Billion ≈ $140.94 Million |
₩-197.98 Billion ≈ $-134.17 Million |
-0.952x | -269.66% |
| 2015-12-31 | ₩86.94 Billion ≈ $58.91 Million |
₩-22.39 Billion ≈ $-15.17 Million |
-0.258x | -- |
About SillaJen Inc
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more